Brokerages Set $41.00 Price Target for Hutchison China MediTech Limited (HCM)

Hutchison China MediTech Limited (NASDAQ:HCM) has received a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that cover the stock, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy recommendation.

Analysts have set a 12 month consensus target price of $41.00 for the company, according to Zacks. Zacks has also given Hutchison China MediTech an industry rank of 178 out of 265 based on the ratings given to its competitors.

Several research firms have commented on HCM. BidaskClub downgraded shares of Hutchison China MediTech from a “buy” rating to a “hold” rating in a research report on Tuesday, March 20th. Zacks Investment Research cut shares of Hutchison China MediTech from a “hold” rating to a “sell” rating in a research note on Thursday, March 15th.

HCM traded down $0.08 on Monday, reaching $32.85. 34,050 shares of the company traded hands, compared to its average volume of 92,590. Hutchison China MediTech has a 52-week low of $18.30 and a 52-week high of $42.25. The company has a market capitalization of $4,378.11, a PE ratio of -150.00 and a beta of 0.42.

Large investors have recently added to or reduced their stakes in the stock. Castleark Management LLC acquired a new position in Hutchison China MediTech during the 4th quarter valued at $177,000. Geode Capital Management LLC acquired a new position in Hutchison China MediTech during the 4th quarter valued at $258,000. Mckinley Capital Management LLC Delaware acquired a new position in Hutchison China MediTech during the 4th quarter valued at $1,237,000. Wells Fargo & Company MN acquired a new position in Hutchison China MediTech during the 4th quarter valued at $1,340,000. Finally, Amundi Pioneer Asset Management Inc. acquired a new position in Hutchison China MediTech during the 4th quarter valued at $2,049,000. Hedge funds and other institutional investors own 7.45% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3382406/brokerages-set-41-00-price-target-for-hutchison-china-meditech-limited-hcm.html.

Hutchison China MediTech Company Profile

Hutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments.

Get a free copy of the Zacks research report on Hutchison China MediTech (HCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Hutchison China MediTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

MediBloc Price Up 8.3% This Week
MediBloc Price Up 8.3% This Week
Factom Market Capitalization Achieves $143.79 Million
Factom Market Capitalization Achieves $143.79 Million
Reviewing Genomic Health  and CareDx
Reviewing Genomic Health and CareDx
Financial Contrast: Valero Energy  and Vertex Energy
Financial Contrast: Valero Energy and Vertex Energy
Comparing Verint Systems  and VASCO Data Security International
Comparing Verint Systems and VASCO Data Security International
Brokerages Anticipate EXFO  Will Announce Earnings of -$0.08 Per Share
Brokerages Anticipate EXFO Will Announce Earnings of -$0.08 Per Share


© 2006-2018 Ticker Report. Google+.